Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
| ▸ | SCN1A | P35498 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.49 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.49 |
| ▸ | KCNA3 | P22001 | 4/20 | 0.35 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3409986 | 1.00 | MEN1 (0.49) | MEN1LMNACYP2D6HRH1SCN1A | |
| SCHEMBL963328 | 1.00 | MEN1 (0.49) | MEN1LMNACYP2D6HRH1SCN1A | |
| Bromide SCHEMBL3491155 | 0.98 | MEN1 (0.47) | MEN1LMNACYP2D6HRH1SCN1A | |
| Bromide SCHEMBL3491157 | 0.98 | MEN1 (0.47) | MEN1LMNACYP2D6HRH1SCN1A | |
| Oxalic Acid SCHEMBL4747187 | 0.93 | MEN1 (0.46) | MEN1LMNACYP2D6HRH1SCN1A | |
| Oxalic Acid SCHEMBL4747189 | 0.93 | MEN1 (0.46) | MEN1LMNACYP2D6HRH1SCN1A | |
| SCHEMBL8424963 | 0.90 | DRD2 (0.40) | MEN1LMNACYP2D6HRH1SCN1A | |
| SCHEMBL8424962 | 0.90 | DRD2 (0.40) | MEN1LMNACYP2D6HRH1SCN1A | |
| SCHEMBL4180834 | 0.90 | HRH1 (0.56) | MEN1LMNACYP2D6HRH1SCN1A | |
| SCHEMBL10360054 | 0.89 | MEN1 (0.38) | MEN1LMNACYP2D6HRH1SCN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144354-A1 | Process for Preparation of Darifenacin and Intermediates Used in the Process | Watson Pharma Private Limited (IN) | 2011-06-16 | — | — | US | claimed |
| EP-2261205-A1 | METHOD OF PRODUCING (S)-3-(1-CYANO-1,1-DIPHENYLMETHYL)-PYRROLIDINE | Kaneka Corporation (JP) | 2010-12-15 | — | — | EP | claimed |
| WO-2010032225-A2 | PROCESS FOR PREPARATION OF DARIFENACIN AND INTERMEDIATES USED IN THE PROCESS | Watson Pharma Private Limited (IN) | 2010-03-25 | — | — | WO | claimed |
| EP-2109601-A2 | PREPARATION OF DARIFENACIN AND ITS SALTS | Dr. Reddy's Laboratories Ltd. (IN) | 2009-10-21 | — | — | EP | claimed |
| WO-2009125430-A2 | IMPROVED PROCESS FOR PRODUCING DARIFENACIN | MATRIX LABORATOIRES LIMITED (IN) | 2009-10-15 | — | — | WO | claimed |
| US-20090156831-A1 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | MERLI VALERIANO | 2009-06-18 | — | — | US | claimed |
| US-20080269503-A1 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICALS USA, INC. FOR BARBADOS | 2008-10-30 | — | — | US | claimed |
| WO-2008126106-A2 | NOVEL AND IMPROVED PROCESSES FOR THE PREPARATION OF INTERMEDIATES OF DARIFENACIN, DARIFENACIN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | SATYANARAYANA REDDY MANNE (IN) | 2008-10-23 | — | — | WO | claimed |
| WO-2008100651-A2 | PREPARATION OF DARIFENACIN AND ITS SALTS | DR. REDDY'S LABORATORIES LTD. (IN) | 2008-08-21 | — | — | WO | claimed |
| EP-1891034-A2 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | Teva Pharmaceutical Fine Chemicals S.R.L. (IT) | 2008-02-27 | — | — | EP | claimed |
| EP-1877393-A2 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | Teva Pharmaceutical Fine Chemicals S.R.L. (IT) | 2008-01-16 | — | — | EP | claimed |
| US-20070203221-A1 | (S)-2-{1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]-3-pyrrolidinyl}-2,2-diphenylacetamide, selective muscarinic acetylcholine receptor antagonists, used for treating urogenital disorders such as incontinence | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-08-30 | — | — | US | claimed |
| US-20070197631-A1 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-08-23 | — | — | US | claimed |
| WO-2007076157-A2 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | TEVA PHARMACEUTICALS INDUSTRIES LTD. (IL) | 2007-07-05 | — | — | WO | claimed |
| WO-2007076158-A2 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-07-05 | — | — | WO | claimed |
| EP-2121594-B1 | QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R & D IP LLC (US) | 2015-10-21 | — | — | EP | disclosed |
| US-8802856-B2 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-5096890-A | PYRROLIDINE DERIVATIVES | PFIZER INC. (US) | 1992-03-17 | — | — | US | disclosed |
| WO-1991009013-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | PFIZER LIMITED (GB) | 1991-06-27 | — | — | WO | disclosed |
| EP-0388054-A1 | Pyrrolidine derivatives | Pfizer Limited (GB) | 1990-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203221-A1 | (S)-2-{1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]-3-pyrrolidinyl}-2,2-diphenylacetamide, selective muscarinic acetylcholine receptor antagonists, used for treating urogenital disorders such as incontinence | CHRNE, CHRM3, CHRM2 | MEN1 4673/4885LMNA 4555/4885CYP2D6 1563/4885 |
| US-20080269503-A1 | Processes for preparing darifenacin hydrobromide | OPRL1, AVPR2, AVPR1B | MEN1 2021/4885LMNA 2545/4885CYP2D6 329/4885 |
| US-20110144354-A1 | Process for Preparation of Darifenacin and Intermediates Used in the Process | OPRL1, OPRD1, OPRK1 | MEN1 4026/4885LMNA 2737/4885CYP2D6 137/4885 |
| US-20070197631-A1 | Processes for preparing darifenacin hydrobromide | OPRL1, AVPR2, AVPR1B | MEN1 2021/4885LMNA 2545/4885CYP2D6 329/4885 |
| US-20090156831-A1 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | OPRL1, AVPR2, AVPR1B | MEN1 2021/4885LMNA 2545/4885CYP2D6 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.